Unlike glucocorticoids, ApN increases insulin sensitivity [4], does not induce muscle atrophy but rather reduces proteolysis [47], upregulates utrophin (our own data) and enhances the myogenic program, prevents obesity [12, 46], and protects against hypertension [48]. The gene discussed is UTRN; the disease is obesity due to melanocortin 4 receptor deficiency.